These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26886305)

  • 1. Pharmaceutical Applications of Relaxation Filter-Selective Signal Excitation Methods for ¹⁹F Solid-State Nuclear Magnetic Resonance: Case Study With Atorvastatin in Dosage Formulation.
    Asada MN; Nemoto T; Mimura H
    J Pharm Sci; 2016 Mar; 105(3):1233-8. PubMed ID: 26886305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of 13C labeling to enhance the sensitivity of 13C solid-state CPMAS NMR to study polymorphism in low dose solid formulations.
    Booy KJ; Wiegerinck P; Vader J; Kaspersen F; Lambregts D; Vromans H; Kellenbach E
    J Pharm Sci; 2005 Feb; 94(2):458-63. PubMed ID: 15614820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state NMR studies of form I of atorvastatin calcium.
    Wang WD; Gao X; Strohmeier M; Wang W; Bai S; Dybowski C
    J Phys Chem B; 2012 Mar; 116(11):3641-9. PubMed ID: 22360640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying Micromolar Crystallinity in Pharmaceutical Materials Utilizing
    Du Y; Phyo P; Li M; Sorman B; McNevin M; Xu W; Liu Y; Su Y
    Anal Chem; 2022 Nov; 94(44):15341-15349. PubMed ID: 36306275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of qualitative and quantitative analysis methods in pharmaceutical application with new selective signal excitation methods for 13 C solid-state nuclear magnetic resonance using 1 H T1rho relaxation time.
    Nasu M; Nemoto T; Mimura H; Sako K
    J Pharm Sci; 2013 Jan; 102(1):154-61. PubMed ID: 23147444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations.
    Brus J; Urbanova M; Sedenkova I; Brusova H
    Int J Pharm; 2011 May; 409(1-2):62-74. PubMed ID: 21356299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of compaction-induced crystallinity reduction of a pharmaceutical solid using 19F solid-state NMR and powder X-ray diffraction.
    Liu J; Nagapudi K; Kiang YH; Martinez E; Jona J
    Drug Dev Ind Pharm; 2009 Aug; 35(8):969-75. PubMed ID: 19360510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 19F solid-state NMR spectroscopic investigation of crystalline and amorphous forms of a selective muscarinic M3 receptor antagonist, in both bulk and pharmaceutical dosage form samples.
    Wenslow RM
    Drug Dev Ind Pharm; 2002 May; 28(5):555-61. PubMed ID: 12098844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced new relaxation filter-selective signal excitation methods for (13)C solid-state nuclear magnetic resonance.
    Asada M; Nemoto T; Mimura H; Sako K
    Anal Chem; 2014 Oct; 86(20):10091-8. PubMed ID: 25225742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹³C cross-polarization magic-angle spinning nuclear magnetic resonance analysis of the solid drug forms with low concentration of an active ingredient-propranolol case.
    Pisklak DM; Zielińska-Pisklak M; Szeleszczuk L; Wawer I
    J Pharm Biomed Anal; 2014 May; 93():68-72. PubMed ID: 23911072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy.
    Offerdahl TJ; Salsbury JS; Dong Z; Grant DJ; Schroeder SA; Prakash I; Gorman EM; Barich DH; Munson EJ
    J Pharm Sci; 2005 Dec; 94(12):2591-605. PubMed ID: 16258988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
    Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
    Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Okada K; Hirai D; Kumada S; Kosugi A; Hayashi Y; Onuki Y
    J Pharm Sci; 2019 Jan; 108(1):451-456. PubMed ID: 30267784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state (13)C CPMAS NMR spectroscopy.
    Virtanen T; Maunu SL
    Int J Pharm; 2010 Jul; 394(1-2):18-25. PubMed ID: 20416365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples.
    Shete G; Puri V; Kumar L; Bansal AK
    AAPS PharmSciTech; 2010 Jun; 11(2):598-609. PubMed ID: 20352531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-state NMR in the analysis of drugs and naturally occurring materials.
    Paradowska K; Wawer I
    J Pharm Biomed Anal; 2014 May; 93():27-42. PubMed ID: 24173236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid-state NMR studies of pharmaceutical solids in polymer matrices.
    Lubach JW; Padden BE; Winslow SL; Salsbury JS; Masters DB; Topp EM; Munson EJ
    Anal Bioanal Chem; 2004 Mar; 378(6):1504-10. PubMed ID: 15214410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding API-polymer proximities in amorphous stabilized composite drug products using fluorine-carbon 2D HETCOR solid-state NMR.
    Abraham A; Crull G
    Mol Pharm; 2014 Oct; 11(10):3754-9. PubMed ID: 25152063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability.
    Lubach JW; Xu D; Segmuller BE; Munson EJ
    J Pharm Sci; 2007 Apr; 96(4):777-87. PubMed ID: 17238201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Evaluation of the Crystallinity of Indomethacin Using
    Okada K; Hayashi Y; Kumada S; Onuki Y
    J Pharm Sci; 2020 Aug; 109(8):2577-2584. PubMed ID: 32473213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.